论文部分内容阅读
目的探讨不同剂量瑞舒伐他汀钙对冠心病患者血脂及超敏C反应蛋白(hs-CRP)的影响。方法选择200例冠心病高脂血症患者,分为常规剂量(10 mg)瑞舒伐他汀钙组(对照组)和加倍剂量(20 mg)瑞舒伐他汀钙组(观察组),观察两组患者血清三酰甘油(TG)、血清总胆固醇(TC)、血清低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、hs-CRP、载脂蛋白A1(Apo A1)、载脂蛋白B(Apo B)、丙氨酸基转移酶(ALT)、肌酸磷酸激酶(CPK)水平,比较其降脂效果、对hs-CRP的影响及安全性。结果通过1个疗程的治疗后,两组TG、TC、LDL-C、hs-CRP、Apo A1、Apo B明显降低(P<0.05),HDL-C明显升高(P<0.05);观察组降低幅度更加明显(P<0.05);两组ALT、CPK升高幅度并不明显;观察组降脂总有效率(92.38%)明显高于对照组(80.00%)(P<0.05)。结论加倍剂量瑞舒伐他汀钙能够有效降低血脂以及hs-CRP,临床疗效显著,而且安全性能良好。
Objective To investigate the effects of different doses of rosuvastatin calcium on serum lipids and hs-CRP in patients with coronary heart disease. Methods 200 patients with coronary heart disease and hyperlipidemia were divided into two groups: control group (rosuvastatin calcium 10 mg) and rosuvastatin calcium 20 mg (observation group) Serum TG, TC, LDL-C, HDL-C, hs-CRP, apolipoprotein A1 (Apo A1, Apo B, ALT and CPK were measured. The effects of lipid-lowering effect and hs-CRP on the safety and safety of hs-CRP were compared. Results After one course of treatment, the levels of TG, TC, LDL-C, hs-CRP, Apo A1 and Apo B were significantly decreased (P <0.05) and HDL-C significantly increased in the two groups (P <0.05). The increase rate of ALT and CPK was not significant in both groups. The total effective rate of lipid lowering in observation group was significantly higher than that in control group (92.38% vs 80.00%, P <0.05). Conclusions Double dose of rosuvastatin calcium can effectively reduce blood lipid and hs-CRP, with significant clinical effect and good safety.